1.
Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
by Kroiss, Matthias
The journal of clinical endocrinology and metabolism, 2012-10, Vol.97 (10), p.3495-3503
2.
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
by Parmar, M K B
The Lancet (British edition), 2003-06-21, Vol.361 (9375), p.2099-2106
3.
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older
by Mizrahi, Jonathan D
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2020-04, Vol.20 (3), p.501-504
4.
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
by Rodenhuis, Sjoerd
The Lancet (British edition), 1998, Vol.352 (9127), p.515-521
5.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lu...
by West, Howard
The lancet oncology, 2019-07, Vol.20 (7), p.924-937
6.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled,...
by Zhu, Andrew X
The lancet oncology, 2019-02, Vol.20 (2), p.282-296
7.
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome
by Mooney, Colin J
Thyroid (New York, N.Y.), 2009-03, Vol.19 (3), p.233-240
8.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
by Rittmeyer, Achim, MD
The Lancet (British edition), 2016, Vol.389 (10066), p.255-265
9.
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH...
by Vilgrain, Valérie
The lancet oncology, 2017-12, Vol.18 (12), p.1624-1636
10.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
by Balar, Arjun V, Dr
The Lancet (British edition), 2016, Vol.389 (10064), p.67-76
11.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
by El-Khoueiry, Anthony B, Dr
The Lancet (British edition), 2017, Vol.389 (10088), p.2492-2502
12.
Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis
by Freda, Pamela U
The journal of clinical endocrinology and metabolism, 2005-08, Vol.90 (8), p.4465-4473
13.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
by Herbst, Roy S, Prof
The Lancet (British edition), 2015, Vol.387 (10027), p.1540-1550
14.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicent...
by Rosenberg, Jonathan E, Dr
The Lancet (British edition), 2016, Vol.387 (10031), p.1909-1920
15.
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
by Haas, Naomi B, Dr
The Lancet (British edition), 2016, Vol.387 (10032), p.2008-2016
16.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
by Italiano, Antoine
The lancet oncology, 2018-05, Vol.19 (5), p.649-659
17.
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
by Koizumi, Wasaburo, Dr
The lancet oncology, 2008, Vol.9 (3), p.215-221
18.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
by Ribas, Antoni, Prof
The lancet oncology, 2015, Vol.16 (8), p.908-918
19.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
by Lonial, Sagar, Prof
The Lancet (British edition), 2016, Vol.387 (10027), p.1551-1560
20.
Design strategies of hybrid metallic nanoparticles for theragnostic applications
by Gautier, J
Nanotechnology, 2013-10-09, Vol.24 (43), p.432002-432002
